Trial reportThe Journal of infectious diseases2025
Viral and Symptom Rebound Following Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Therapy in a Randomized Placebo-Controlled Trial.
Kara W Chew, Brooke McGinley, Carlee Moser, Jonathan Z Li, Teresa H Evering, Justin Ritz, Arzhang Cyrus Javan, David Margolis, David A Wohl, Michael D Hughes and 5 more
Abstract readClinical Trial, Phase IIClinical Trial, Phase IIIMulticenter Study
In one paragraphTrial report in The Journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
15 authors.
Kara W ChewDepartment of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.ORCID 0000-0003-4865-4348 Brooke McGinleyDepartment of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA.ORCID 0000-0001-9717-6165 Carlee MoserCenter for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.ORCID 0000-0001-5601-9112 Jonathan Z LiDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0001-9914-9662 Teresa H EveringDepartment of Medicine, Weill Cornell Medicine, New York, New York, USA.
Justin RitzCenter for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.
Arzhang Cyrus JavanDivision of AIDS/National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA.
David MargolisBrii Biosciences, Durham, North Carolina, USA.
David A WohlDepartment of Medicine, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.ORCID 0000-0002-7764-0212 Michael D HughesCenter for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.
Eric S DaarLundquist Institute at Harbor-UCLA Medical Center, Torrance, California, USA.
Judith S CurrierDepartment of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Joseph J EronDepartment of Medicine, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.ORCID 0000-0002-4938-0644 Davey M SmithDepartment of Medicine, University of California, San Diego, La Jolla, California, USA.
Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)-2/A5401 Study Team, Study Sites, and Investigators
Funding
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1MStatistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6MAIDS Clinical Trials Group NetworkU01AI068636 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI KURITZKES, DANIEL R. · 2006 to 2010
$147.1MUCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1MValidation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8MUCLA AIDS Prevention and Treatment Clinical Trials UnitUM1AI069424 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Judith S. Currier, RAPHAEL J LANDOVITZ · 2012 to 2026
$51.8MWeill Cornell Medicine - Rutgers New Jersey Medical School Clinical Trials UnitUM1AI069419 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI ROY M. GULICK · 2012 to 2026
$44.6MWits HIV Research Group CLINICAL TRIAL UNIT (CTU) reapplicationUM1AI069463 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI REES, HELEN, SANNE, IAN MATTHIAS · 2012 to 2025
$31.8MUnits for HIV/AIDS Clinical Trials NetworksU01AI069463 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI SANNE, IAN MATTHIAS · 2007 to 2011
$24.2MNational Institute of Allergy and Infectious DiseasesNCATS NIH HHS UL1 TR001881NIAID NIH HHS U01 AI068636NIAID NIH HHS U01 AI069463NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI069419NIAID NIH HHS UM1 AI069424NIAID NIH HHS UM1 AI069463NIAID NIH HHS UM1 AI106701NIH HHS UM1AI068636
6 · The paper itselfAbstract
We explored viral and symptom rebound after coronavirus disease 2019 amubarvimab-romlusevimab monoclonal antibody therapy versus placebo in the randomized ACTIV-2/A5401 trial. Participants underwent nasal severe acute respiratory syndrome coronavirus 2 polymerase chain reaction testing at study days 3, 7, 14, and 28. Viral rebound was defined as RNA ≥3 and ≥0.5 log10 copies/mL increase from day 3 or 7, and symptom rebound as hospitalization or any moderate/severe symptom for ≥2 days after initial symptom improvement. There was no difference in viral rebound (∼5%/arm) (analysis population n = 713) or symptom rebound among participants who initially improved (hazard ratio, 0.95 [95% confidence interval, .52-1.75]; analysis population n = 574); <1% had both viral/symptom rebound.
Indexed as
Antibodies, Monoclonal, HumanizedAntibodies, NeutralizingCOVID-19COVID-19 Drug TreatmentSARS-CoV-2AdultAgedDouble-Blind MethodFemaleHumansMaleMiddle AgedRNA, ViralTreatment OutcomeViral LoadamubarvimabAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingRNA, ViralromlusevimabCOVID-19monoclonal antibodiesnonhospitalized adultsSARS-CoV-2symptom reboundviral rebound
Identifiers
PMID39400063
PMCPMC11793053
What OpenQuestion holds
Textmetadata
Read underepoch 390